Tonix Pharmaceuticals Holding Corp.
TNXP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $3 | $2 | $2 | $3 |
| % Growth | 64.7% | -17.7% | -5.9% | – |
| Cost of Goods Sold | $1 | $3 | $1 | $1 |
| Gross Profit | $2 | -$1 | $1 | $1 |
| % Margin | 58.4% | -63.8% | 61.2% | 54.2% |
| R&D Expenses | $9 | $11 | $7 | $8 |
| G&A Expenses | $0 | $0 | $10 | $3 |
| SG&A Expenses | $0 | $0 | $10 | $16 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $12 |
| Other Operating Expenses | $26 | $16 | $0 | $0 |
| Operating Expenses | $35 | $27 | $18 | $24 |
| Operating Income | -$33 | -$28 | -$16 | -$22 |
| % Margin | -1,005.1% | -1,416.2% | -660.9% | -870.6% |
| Other Income/Exp. Net | $1 | $0 | -$1 | $0 |
| Pre-Tax Income | -$32 | -$28 | -$17 | -$22 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$32 | -$28 | -$17 | -$22 |
| % Margin | -972.9% | -1,415% | -692.8% | -856.2% |
| EPS | -3.59 | -3.86 | -2.84 | -9.77 |
| % Growth | 7% | -35.9% | 70.9% | – |
| EPS Diluted | -3.59 | -3.86 | -2.84 | -9.77 |
| Weighted Avg Shares Out | 9 | 7 | 6 | 2 |
| Weighted Avg Shares Out Dil | 9 | 7 | 6 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$32 | -$28 | -$16 | -$22 |
| % Margin | -958.9% | -1,392% | -672.5% | -837% |